Table 2 Comparison between ATP-accelerated group and ATP non-accelerated group according to baseline characteristics
From: Arrhythmogenicity of anti-tachycardia pacing in patients with implantable cardioverter defibrillator
Baseline characteristics | ATP accelerated group (n = 17) | ATP non-accelerated group (n = 43) | Test | P-value |
|---|---|---|---|---|
Sex | ||||
Female | 2 (11.8%) | 4 (9.3%) | χ2 = 0.082 | 0.774 |
Male | 15 (88.2%) | 39 (90.7%) | ||
Age (years) | ||||
Mean ± SD | 56.59 ± 9.31 | 56.60 ± 9.60 | 0.126 | 0.895 |
Range | 39–72 | 38–80 | ||
Diagnosis | ||||
ARVD | 1 (5.9%) | 1 (2.3%) | χ2 = 3.733 | 0.292 |
DCM | 3 (17.6%) | 13 (30.2%) | ||
HOCM | 1 (5.9%) | 0 (0.0%) | ||
ICM | 12 (70.6%) | 29 (67.4%) | ||
Indications | ||||
Primary | 1 (5.9%) | 3 (7.0%) | χ2 = 0.023 | 0.878 |
Secondary | 16 (94.1%) | 40 (93.0%) | ||
AAD therapy | ||||
BB | 5 (29.4%) | 17(39.5%) | χ2 = 8.266 | 0.142 |
BB + Amiodarone | 8 (41.2%) | 13(16.3%) | ||
BB + Ivabradine | 0 (0.0%) | 3 (7.0%) | ||
Amiodarone + Ivabradine | 0 (0.0%) | 2 (2.3%) | ||
BB + Amiodarone + Ivabradine | 1 (0.0%) | 1 (2.3%) | ||
BB + Sotalol | 2 (5.9%) | 0 (0.0%) | ||
BB + Amiodarone + Sotalol | 0 (0.0%) | 3 (2.3%) | ||
Amiodarone | 0 (0.0%) | 1 (2.3%) | ||
Digoxin | 0 (0.0%) | 1 (2.3%) | ||
Ivabradine + Sotalol | 1 (5.9%) | 0 (0.0%) | ||
Ivabradine + Digoxin | 0 (0.0%) | 1 (2.3%) | ||
Sotalol | 0 (0.0%) | 1 (2.3%) | ||
EF% | ||||
Mean ± SD | 31.24 ± 7.08 | 37.00 ± 9.04 | 2.565 | 0.016* |
Range | 21–55 | 24–62 | ||